Denotes a link to the speaker's bio page.
This opening session will discuss the backdrop of national regulatory and policy frameworks enabling the advancement of precision oncology, examining the barriers and possible solutions being found to overcome these. A panel of leading experts will share their own perspectives on the following points, followed by extended audience Q&A discussion.
- Identifying the current legal, regulatory and ethical obstacles restricting the advancement of precision medicine
- Exploring ways in which regulatory frameworks need to adapt to overcome these obstacles, and enable innovation and delivery, esp with regards to:
- data access and sharing
- the use of AI and machine learning in precision oncology
- Examining how the disease and drug classification and reimbursement system could change to enable a broader, biological approach
- Assessing the effectiveness of European Reference Networks and how these could be enhanced and aligned with national healthcare systems:
- how close are we to enabling cancer treatment across borders?
The effective implementation of precision medicine needs collaborative approaches, both national and cross-border. Identifying and bringing together different stakeholders, and finding appropriate financial mechanisms are key elements; as well as a need to encourage multi-institutional and cross-border collaboration and facilitate transparent and effective data-sharing. This session will explore what can, and is being, achieved, through different European projects and what further lessons could perhaps be learnt from international experiences..
This session is intended to give participants the opportunity to discuss a specific topic in a more informal, participative format. Delegates may choose one roundtable to attend, and each table will be led by a facilitator who will outline some structured points for discussion and encourage optimum debate and exchange of ideas.
A. The Policy Perspective: Precision Oncology Requires Innovation in HTA Legislation & Regulation
B. Computational Biology for Drug Discovery: Leveraging Cancer Genomics Data to Aid Discovery of Novel Targets and Biomarkers
C. Innovative Approaches to Clinical Trial Design
Prof Dr Kjetil Taskén, Head & Director, Institute for Cancer Research - Norwegian Radium Hospital and Group Leader, Dept of Cancer Immunology, Oslo University Hospital. Professor, Institute of Clinical Medicine, University of Oslo
D. Immuno-Oncology: Exploring Advances in Cancer Immunotherapies
E. Liquid Biopsy: Circulating Tumour DNA & Bloodborne Biomarkers as Diagnostic Tools
F. Making it a Reality: Implementing Precision Oncology into Clinical Practice
G. The Patient’s Perspective: Patients as a Driving-Force to Advance Precision Medicine
Each roundtable facilitator will briefly share the key learning points from their table discussion with the audience.
Close of Day One followed by a Complimentary Networking Drinks Reception
A greater understanding of disease and the realisation that cancer can no longer be defined in basic terms, is having a significant impact on clinical trials and drug development. Innovations in clinical trial design, and better understanding how to classify patients, including selection for novel cancer immunotherapies, has the potential to accelerate research and drug development so that the right therapies can rapidly be delivered to the right patients.
However, new approaches to clinical trials and the development of precision oncology require a change in the approach to research and data-gathering and its application to clinical practice. There is a growing need to analyse a broader range of clinical outcomes within research, treatment evaluation and reimbursement decisions. This session will explore the implications of re-thinking clinical trial design and some of the results already being achieved.
Prof Andrew V. Biankin, Regius Professor of Surgery, Director, Wolfson Wohl Cancer Research Centre, Executive Director, International Cancer Genome Consortium, Director, Glasgow Precision Oncology Laboratory, Chair, Precision-Panc Therapeutic Development Platform, University of Glasgow
The understanding of tumour structure and evolution in cancer is fundamental to the advancement of precision oncology, enabling the identification of genomic alteration in key genes and pathways that can then be targeted with appropriate therapies. However molecular heterogeneity presents major challenges to effective cancer therapy and much effort is still needed to understand the molecular biology and clinical behaviour of heterogeneous and constantly evolving tumours and unravel the mechanisms of drug resistance in order to drive the development of effective precision strategies.
Chair: Prof Dr Kjetil Taskén, Head & Director,Institute for Cancer Research - Norwegian Radium Hospital and Group Leader, Dept of Cancer Immunology, Oslo University Hospital. Professor, Institute of Clinical Medicine, University of Oslo
A significant barrier to the advancement of precision medicine in practice is regarding economics, the perception of “value” and developing effective reimbursement mechanisms to meet the requirements of the payer. This session will examine the potential challenges encountered when demonstrating the economic case for precision oncology and assess the key criteria on which decisions on where to invest are made. It will also discuss solutions for deploying new evidence-based testing and technologies quickly and efficiently, and managing the difficult balance between value economics and optimum patient care.
Clinical Decision Support & Analytics Tools in Precision Oncology - Changing the Paradigm in Evidence Generation?
Exploring How to Move towards Precision Immunotherapy
Innovations in Imaging Technology and Radiology to Advance Precision Oncology
Challenges, Opportunities and Newest Applications for Molecular Tumour Diagnostics